Harper Hubbeling

2.8k total citations
29 papers, 1.6k citations indexed

About

Harper Hubbeling is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Harper Hubbeling has authored 29 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Harper Hubbeling's work include Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Brain Metastases and Treatment (5 papers). Harper Hubbeling is often cited by papers focused on Lung Cancer Research Studies (8 papers), Lung Cancer Treatments and Mutations (7 papers) and Brain Metastases and Treatment (5 papers). Harper Hubbeling collaborates with scholars based in United States, Mexico and United Kingdom. Harper Hubbeling's co-authors include Jennifer A. Punt, Frédéric Geissmann, Catherine C. Hedrick, Richard N. Hanna, Leo M. Carlin, Angela M. Green, Dominika Nąckiewicz, Justin F. Gainor, Alice T. Shaw and Emily S. Lebow and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Immunology.

In The Last Decade

Harper Hubbeling

24 papers receiving 1.6k citations

Peers

Countries citing papers authored by Harper Hubbeling

Since Specialization

Citations

This map shows the geographic impact of Harper Hubbeling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harper Hubbeling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harper Hubbeling more than expected).

Fields of papers citing papers by Harper Hubbeling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Harper Hubbeling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harper Hubbeling. The network helps show where Harper Hubbeling may publish in the future.

Co-authorship network of co-authors of Harper Hubbeling

This figure shows the co-authorship network connecting the top 25 collaborators of Harper Hubbeling. A scholar is included among the top collaborators of Harper Hubbeling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harper Hubbeling. Harper Hubbeling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pembrolizumab in Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome 2025 ·JAMA Dermatology ·(unknown), Jonathan Sussman, (unknown), Colin Thomas, (unknown), Daniel J. Landsburg, Jakub Svoboda, Ellen Kim, Alain H. Rook, Jina Chung, John P. Plastaras, Michael J. LaRiviere, Harper Hubbeling, Monica Chelius, Sunita D. Nasta, Elise A. Chong, Stephen J. Schuster, Stefan K. Barta	0
2	Outcomes of radiation integrated with T-cell–engaging bispecific antibodies in relapsed/refractory multiple myeloma 2025 ·Blood Advances ·(unknown), Harper Hubbeling, Kang Yu, (unknown), Michael J. LaRiviere, John P. Plastaras, Adam D. Cohen, (unknown), Dan T. Vogl, Adam Waxman, Edward A. Stadtmauer, Alfred L. Garfall, Sandra P. Susanibar-Adaniya	0
3	Outcomes of proton therapy to infradiaphragmatic sites in pediatric patients with Hodgkin lymphoma 2024 ·Pediatric Blood & Cancer ·(unknown), Michele M. Kim, Xiaoyan Han, Monica Chelius, (unknown), Leslie S. Kersun, Anne F. Reilly, Harper Hubbeling, Elizabeth Cummings, Goldie Kurtz, Christine E. Hill‐Kayser, John P. Plastaras, Michael J. LaRiviere	2
4	Outcomes of Palliative Whole Posterior Fossa Radiotherapy for Adult Brain Metastases 2024 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), (unknown), Emily S. Lebow, Harper Hubbeling, James D. Kolker, S. Nagda, Goldie Kurtz, Michelle Alonso‐Basanta	0
5	Radiation in a New Era of Multiple Myeloma Management: Patterns of Utilization, Clinical, Radiologic, and Biochemical Outcomes, and Possible Genomic Correlates of Response 2023 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), (unknown), Jennifer Ma, Reith Sarkar, (unknown), G. Cederquist, Harper Hubbeling, Kathryn R. Tringale, N. Ari Wijetunga, Saad Z. Usmani, Carla Hajj, Brandon S. Imber, (unknown)	0
6	CNS Radiotherapy As Bridging Prior to CAR T-Cell Therapy for Non-Hodgkin B-Cell Lymphoma 2023 ·Blood ·G. Cederquist, Javin Schefflein, Sean M. Devlin, Harper Hubbeling, Kathryn R. Tringale, Gunjan L. Shah, Ana Alarcón Tomás, Roni Shouval, Carla Hajj, (unknown), Parastoo B. Dahi, Richard J. Lin, Maria Lia Palomba, Miguel‐Angel Perales, Gilles Salles, Lorenzo Falchi, (unknown), Michael Scordo, (unknown), Brandon S. Imber	1
7	Radiotherapy As an Effective Bridge for Relapsed/Refractory Secondary CNS Lymphoma 2023 ·Blood ·G. Cederquist, Kathryn R. Tringale, Carla Hajj, Harper Hubbeling, Jennifer Ma, (unknown), (unknown), Gilles Salles, (unknown), Michael Scordo, Lorenzo Falchi, (unknown), Brandon S. Imber	1
8	Characterization of Central Nervous System Clinico-Genomic Outcomes in ALK-Positive Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Alectinib 2023 ·Lung Cancer ·(unknown), (unknown), Emily S. Lebow, Jessica Flynn, Zhigang Zhang, Henry Walch, Harper Hubbeling, Kathryn Beal, Nelson S. Moss, Kenny Kwok Hei Yu, (unknown), Daniel W. Kelly, Daniel R. Gomez, Bob T. Li, Andreas Rimner, Nikolaus Schultz, Alexander Drilon, Brandon S. Imber, Luke Pike	5
9	Patterns of Relapse and Risk Reduction Following Tumor Debulking by Bridging Radiotherapy prior to Chimeric Antigen Receptor T Cell Therapy in Non-Hodgkin Lymphoma 2022 ·International Journal of Radiation OncologyBiologyPhysics ·Harper Hubbeling, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
10	Trends in Use of and Medicare Spending on Short-Course Radiotherapy for Lymphomas From 2015 to 2019 2022 ·JAMA Health Forum ·Kathryn R. Tringale, Harper Hubbeling, Fumiko Chino, Carla Hajj, (unknown), Brandon S. Imber	2
11	Initial Treatment Response Is Prognostic and Predictive of Relapse Patterns: Outcomes of >500 Patients Treated for Primary CNS Lymphoma 2022 ·Blood ·Kathryn R. Tringale, (unknown), Michael Scordo, G. Cederquist, Behroze Vachha, Lauren Schaff, Carla Hajj, Harper Hubbeling, Zhigang Zhang, (unknown), (unknown), Brandon S. Imber	2
12	Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity 2019 ·Clinical Cancer Research ·Ibiayi Dagogo‐Jack, Marguerite Rooney, W. Marston Linehan, Rebecca J. Nagy, Beow Y. Yeap, Harper Hubbeling, Emily Chin, Jennifer Ackil, Anna F. Farago, Aaron N. Hata, Jochen K. Lennerz, Justin F. Gainor, Richard B. Lanman, Alice T. Shaw	112
13	Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non–Small Cell Lung Cancer 2018 ·Journal of Thoracic Oncology ·Harper Hubbeling, Emily S. Lebow, Nora Horick, (unknown), W. Marston Linehan, Kevin Oh, Alice T. Shaw, William A. Mehan, Helen A. Shih, Justin F. Gainor	95
14	Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases 2018 ·International Journal of Radiation OncologyBiologyPhysics ·Emily S. Lebow, Harper Hubbeling, Beow Y. Yeap, William A. Mehan, Alice T. Shaw, Kevin Oh, Justin F. Gainor, Helen A. Shih	104
15	Psychosocial needs of young breast cancer survivors in Mexico City, Mexico 2018 ·PLoS ONE ·Harper Hubbeling, Shoshana M. Rosenberg, María Cecilia González-Robledo, (unknown), Cynthia Villarreal‐Garza, Ann H. Partridge, Felícia Marie Knaul	49
16	Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer 2017 ·JCO Precision Oncology ·Justin F. Gainor, Diane Tseng, Satoshi Yoda, Ibiayi Dagogo‐Jack, Luc Friboulet, W. Marston Linehan, Harper Hubbeling, Leila Dardaei, Anna F. Farago, Katherine R. Schultz, Lorin A. Ferris, Zofia Piotrowska, James C.H. Hardwick, Donghui Huang, Mari Mino–Kenudson, A. John Iafrate, Aaron N. Hata, Beow Y. Yeap, Alice T. Shaw	200
17	Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy 2017 ·JAMA Oncology ·William L. Hwang, Andrzej Niemierko, Katie L. Hwang, Harper Hubbeling, Emily S. Lebow, Justin F. Gainor, Florence K. Keane	69
18	Conventional CD4+ T cells regulate IL-22-producing intestinal innate lymphoid cells 2014 ·Mucosal Immunology ·(unknown), (unknown), Harper Hubbeling, Sean P. Spencer, Rohini Sinha, (unknown), Nita H. Salzman, Frederic D. Bushman, Terri M. Laufer	64
19	Regulatory T Cells Occupy an Isolated Niche in the Intestine that Is Antigen Independent 2014 ·Cell Reports ·(unknown), Harper Hubbeling, Paige M. Porrett, Qi Yang, Lisa G. Barnett, Terri M. Laufer	27
20	The transcription factor NR4A1 (Nur77) controls bone marrow differentiation and the survival of Ly6C− monocytes 2011 ·Nature Immunology ·Richard N. Hanna, Leo M. Carlin, Harper Hubbeling, Dominika Nąckiewicz, Angela M. Green, Jennifer A. Punt, Frédéric Geissmann, Catherine C. Hedrick	481

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact